Stone NJ, Robinson JG, Lichtenstein AH et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol, 2014, 63(25 pt B): 2889-2934.
Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016, 37: 2999-3058.
Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015, 372: 2387-2397.
Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017, 376: 1713-1722.
Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med, 2008, 359: 2195-2207.
Cannon CP, Khan I, Klimchak AC et al. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease [published online August 2, 2017]. JAMA Cardiol, doi:10.1001 /jamacardio.2017.2289..
DOI: 10.1001 /jamacardio.2017.2289
Virani SS, Akeroyd JM, Nambi V et al. Estimation of eligibility for PCSK9 inhibitors and associated costs based on the FOURIER trial: insights from the Department of Veterans Affairs. Circulation, 2017, 135: 2572-2574.
Smith SC Jr. Defining Potential Use of Nonstatin Therapies to Lower Blood Cholesterol Levels. JAMA Cardiol, 2017 Aug 2. doi: 10.1001/jamacardio.2017.2290. [Epub ahead of print]..
DOI: 10.1001/jamacardio.2017.2290. [Epub ahead of print]
Kazi DS, Moran AE, Coxson PG et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA, 2016, 316: 743-753.
Kazi DS, Moran AE, Bibbins-Domingo K. Cost-effectiveness of PCSK9 inhibitor therapy-reply. JAMA, 2016, 316: 2152.
Svatikova A, Kopecky SL. Cholesterol Management in the Era of PCSK9 Inhibitors. Curr Cardiol Rep, 2017, 19: 83.
Anderson JL, Heidenreich PA, Barnett PG et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association task force on performance measures and task force on practice guidelines. J Am Coll Cardiol, 2014, 63: 2304-2322.
Tice JA, Kazi DS, Pearson SD. Proprotein con-vertase subtilisin/ kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: effectiveness and value. JAMA Intern Med, 2016, 176: 107-108.
Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol, 2003, 92: 152-160.
McKenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin, 2003, 19: 689-698.
Pitt B, Loscalzo J, Monyak J et al. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). Am J Cardiol, 2012, 109: 1239-1246.
Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of sta-tin therapy. Lancet, 2016, 388: 2532-2561.